The Effect of Duration of Use of Depomedroxyprogesterone Acetate on the Thickness of the Vaginal Epithelium of Mice
DOI:
https://doi.org/10.3889/oamjms.2021.5574Keywords:
Effect of duration, Depomedroxyprogesterone acetate, Vaginal epitheliumAbstract
BACKGROUND: Depomedroxyprogesterone acetate (DMPA) is one of the most effective contraceptive methods currently widely used. Injectable contraceptives, including DMPA, are growing in popularity because of their ease of use, effectiveness and affordability. The use of DMPA also has advantages such as not interfering with sexual relations, does not need male participation, does not require storage space, and is easy to obtain and helps increase body weight.
AIM: The aim of the study was to analyze the effect of the duration of use of DMPA on the thickness of the vaginal epithelium of mice.
METHODS: The research design used in this study was true experimental with a post-test only control group design approach. This research was carried out treatment at a dose of 0.39 mg/mouse/day DMPA exposure in mice. The phenomenon observed in this study was the thickness of the vaginal epithelium of mice. This study used mice with the completely randomized design method and was carried out at the Pharmacology Laboratory and the Anatomical Pathology Laboratory, FKH Unsyiah. The collection of data technique was conducted by observation with a light microscope to calculate the average thickness of the vaginal epithelium of mice injected with DMPA in the four groups. The data analysis technique was carried out in five stages, namely, the normality test of the sample data with the Shapiro–Wilk test, the homogeneity test of variance with the Levene test, and comparing the thickness of the vaginal epithelium in each of the two treatment groups using the independent t-test.
RESULTS: The finding revised that there was a significant difference in the thickness of the vaginal epithelium in the two treatment groups 10 days and 15 days of DMPA exposure which was indicated by a p = 0.003 (p < 0.05). DMPA exposure levels cause thinning of the vaginal epithelial thickness. The average thickness of vaginal epithelium exposure to DMPA for 10 days in the control group was 182536.33 ± 5773.465. In the treatment group, exposure to DMPA for 10 days, the thickness of the vaginal epithelium was 168322.33 ± 7611.300. The mean vaginal epithelial thickness in the 15-day DMPA exposure group in the control group was 177242.83 ± 9689.558. In the 15-day DMPA exposure treatment group, the thickness of the vaginal epithelium was 138674.83 ± 17176.124.
CONCLUSION: There was a difference in the mean vaginal epithelial thickness between the control group and 10 days of DMPA exposure. There was a difference in the mean vaginal epithelial thickness between the control group and 15 days of DMPA exposure. The longer the exposure to DMPA, the thinner the thickness of the vaginal epithelium.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
World Health Organization. Keluarga Berencana/Kontrasepsi. Geneva: World Health Organization; 2019.
Cates W Jr., Karim QA, El-Sadr W, Haffner DW, KalemaZikusoka G, Rogo K, et al. Global development. Family planning and the millennium development goals. Science. 2010;329(5999):1603. https://doi.org/10.1126/science.1197080 PMid:20847233
Habumuremyi PD, Zenawi M. Making family planning a national development priority. Lancet. 2012;380(9837):78-80. https://doi.org/10.1016/s0140-6736(12)60904-0 PMid:22784539
United Nations, Department of Economic and Social Affairs, Population Division World Contraceptive Use 2012, UN Report; 2012.
BPS, BKKBN, Kemenkes, ICF. Survei Demografi dan Kesehatan Indonesia. Jakarta: BPS; 2012.
Affandi B. Long-acting progestogens. Best Pract Res Clin Obstet Gynaecol. 2002;16(2):169-79. PMid:12041960
Gafar A, Suza DE, Efendi F, Has EM, Pramono AP, Susanti IA. Determinants of contraceptive use among married women in Indonesia. F1000Res. 2020;9:193. https://doi.org/10.12688/f1000research.22482.1 PMid:32269768
Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2012. Jakarta: Kementerian Kesehatan Republik Indonesia; 2012. https://doi.org/10.7454/jki.v19i3.469
Veisi F, Zangeneh M. Comparison of two different injectable contraceptive methods: Depo-medroxy progesterone acetate (DMPA) and cyclofem. J Family Reprod Health. 2013;7(3):109-13. PMid:24971112
Gisselquist D. Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis. 2012;12(7):510. https://doi.org/10.1016/s1473-3099(12)70115-9 PMid:22742633
Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS. 2013;27(1):105-13. https://doi.org/10.1097/qad.0b013e32835a5a52 PMid:23014519
Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: A systematic review of the epidemiological evidence. Lancet Infect Dis. 2013;13(9):797-808. https://doi.org/10.1016/s1473-3099(13)70155-5 PMid:23871397
Dalimoenthe I. Women in the Grip of HIV / AIDS: A Household Feminist Sociological Study of Housewives. J Komunitas. 2011;5(1):41-8.
Chandra N, Thurman AR, Anderson S, Cunningham TD, Yousefieh N, Mauck C, et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses. 2013;29(3):592-601. https://doi.org/10.1089/aid.2012.0271 PMid:23189932
Bahamondes MV, Castro S, Marchi NM, Marcovici M, Andrade LA, Fernandes A, et al. Human vaginal histology in long-term users of the injectable contraceptive depotmedroxyprogesterone acetate. Contraception. 2014;90(2):117- 22. https://doi.org/10.1016/j.contraception.2014.01.024 PMid:24613369
Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31(1):79- 97. https://doi.org/10.1210/er.2009-0018 PMid:19903932
Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011;12(11):233. PMid:22078297
Jain JK, Li A, Yang W, Minoo P, Felix JC. Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate. Hum Reprod. 2006;21(3):798-809. https://doi.org/10.1093/humrep/dei383 PMid:16311300
Lizarelli PM, Martins WP, Vieira CS, Soares GM, FranceschiniSA, Ferriani RA, et al. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception. 2009;79(1):35-40. https://doi.org/10.1016/j.contraception.2008.07.024 PMid:19041439
Krikun G, Buhimschi IA, Hickey M, Schatz F, Buchwalder L, Lockwood CJ. Long-term progestin contraceptives (LTPOC) induce aberrant angiogenesis, oxidative stress and apoptosis in the guinea pig uterus: A model for abnormal uterine bleeding in humans. J Angiogenes Res. 2010;2:8. https://doi.org/10.1186/2040-2384-2-8 PMid:20423489
Walker C, Badawy SZ. Vaginal atrophy following long-term depot medroxyprogesterone acetate use: A case report. Case Rep Obstet Gynecol. 2013;2013:835316. https://doi.org/10.1155/2013/835316 PMid:23533869
Haider Z, D’Souza R. Non-contraceptive benefits and risks of contraception. Best Pract Res Clin Obstet Gynaecol. 2009;23(2):249-62. PMid:19196552
Downloads
Published
How to Cite
License
Copyright (c) 2021 Nora Veri, Cut Mutiah, Dewita Dewita, Henniwati Henniwati (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0